Pharmacokinetics of hepatitis C virus NS5A inhibitor JNJ-56914845 (GSK2336805) in subjects with hepatic impairment.

about

Global elimination of hepatitis C virus infection: Progresses and the remaining challenges.

P2860

Q47274792-D341D82F-F261-450A-B806-DEF5AA6535E3

P2860

Pharmacokinetics of hepatitis C virus NS5A inhibitor JNJ-56914845 (GSK2336805) in subjects with hepatic impairment.

Item

http://www.wikidata.org/entity/Q42149746

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Pharmacokinetics of hepatitis ...... jects with hepatic impairment.

@en

Pharmacokinetics of hepatitis C virus NS5A inhibitor JNJ-56914845

@nl

type

Item

label

Pharmacokinetics of hepatitis ...... jects with hepatic impairment.

@en

Pharmacokinetics of hepatitis C virus NS5A inhibitor JNJ-56914845

@nl

prefLabel

Pharmacokinetics of hepatitis ...... jects with hepatic impairment.

@en

Pharmacokinetics of hepatitis C virus NS5A inhibitor JNJ-56914845

@nl

P1476

Pharmacokinetics of hepatitis ...... jects with hepatic impairment.

@en

P2093

Christopher Galloway

http://www.w3.org/2001/XMLSchema#string

Etienne Dumont

http://www.w3.org/2001/XMLSchema#string

Jianjun Gan

http://www.w3.org/2001/XMLSchema#string

Joanne Saunders

http://www.w3.org/2001/XMLSchema#string

Jolene Berg

http://www.w3.org/2001/XMLSchema#string

Kimberly K Adkison

http://www.w3.org/2001/XMLSchema#string

Lori S Jones

http://www.w3.org/2001/XMLSchema#string

Lucinda Elko-Simms

http://www.w3.org/2001/XMLSchema#string

Patrick J Stump

http://www.w3.org/2001/XMLSchema#string

Stephen Gardner

http://www.w3.org/2001/XMLSchema#string

P2860

The effect of liver cirrhosis on the regulation and expression of drug metabolizing enzymes.

Alcohol cirrhosis alters nuclear receptor and drug transporter expression in human liver.

Malnutrition in end stage liver disease: recommendations and nutritional support.

Safety, tolerability, pharmacokinetics, and antiviral activity of GSK2336805, an inhibitor of hepatitis C virus (HCV) NS5A, in healthy subjects and subjects chronically infected with HCV genotype 1

A double-blind, randomized, placebo-controlled study to assess the safety, antiviral activity and pharmacokinetics of GSK2336805 when given as monotherapy and in combination with peginterferon alfa-2a and ribavirin in hepatitis C virus genotype 1-in

Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases.

Preclinical characterization of GSK2336805, a novel inhibitor of hepatitis C virus replication that selects for resistance in NS5A

Effects of omeprazole and ritonavir on absorption and elimination of the hepatitis C virus NS5A inhibitor GSK2336805 in healthy adults.

Novel spiroketal pyrrolidine GSK2336805 potently inhibits key hepatitis C virus genotype 1b mutants: from lead to clinical compound.

Hepatitis C virus-related cirrhosis is a major determinant of the expression levels of hepatic drug transporters.

P304

1042-1050

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/JCPH.512

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-04-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25857714

http://www.w3.org/2001/XMLSchema#string

Pharmacokinetics of hepatitis C virus NS5A inhibitor JNJ-56914845 (GSK2336805) in subjects with hepatic impairment.

about

P2860

P2860

Pharmacokinetics of hepatitis C virus NS5A inhibitor JNJ-56914845 (GSK2336805) in subjects with hepatic impairment.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698